Antibody Forum – Part 1

 

Discovery on Target’s Antibody Forum offers R&D research scientists the opportunity to participate in a unique meeting format that encourages discussion and the exchange of best practices on the application of new science and technology for the discovery and development of novel biotherapeutics. The meeting will feature short presentations, panel discussions, facilitated roundtables and an audience layout that allows a sharing of ideas and experiences. Part 1 will focus on the discovery stage, offering ideas on how to accelerate and optimize these steps, emerging discovery technologies and the integration of artificial intelligence and machine learning.


Preliminary Agenda

OPTIMIZING THE DISCOVERY WORKFLOW

KEYNOTE PRESENTATION: Talk Title to be Announced
Partha S. Chowdhury, PhD, Senior Director and Head, Antibody Discovery, Sanofi Genzyme

Functional Interrogation of Antibody Repertoire at Single Cell Level
Yuxing Cheng, PhD, Principal Scientist, Antibody Discovery, Pfizer

Integrated Antibody Discovery Platforms
Jane Seagal, PhD, Senior Scientist, Biologics Generation Group, AbbVie Bioresearch Center

DISCOVERY WORKFLOW CASE STUDIES

Talk Title to be Announced        
Irwin Chen, PhD, Principal Scientist, Selection and Platform Engineering, Amgen

Leveraging Computational Approaches in Antibody Workflows: Discovery, Design and Engineering
Luke Robinson, PhD, Associate Director, Research, Visterra

High-Throughput Production of Antibodies Using Yeast and Mammalian Cells
Rebecca Hurley, Ph.D., Scientist, High Throughput Expression, Adimab

Talk Title to be Announced         
Speaker to be Announced AbCellera

PANEL DISCUSSION

Emerging Discovery Technologies
Moderator: Andrew Bradbury, PhD, MB BS (MD), CSO, Specifica, Inc.

MACHINE LEARNING AND AI FOR ANTIBODY AND PROTEIN ENGINEERING

Transitioning from Traditional Computational Modeling to Machine Learning and AI
Enkelejda Miho, PhD, Professor, Digital Life Sciences, FHNW University of Applied Sciences and Arts Northwestern Switzerland, Switzerland

HIGH THROUGHPUT FUNCTIONAL SCREENING

Towards Pharmacokinetic Measurements of Hundreds of Individual Multi-Specific Binding Proteins in a Single Experiment
Pascal Egloff, PhD, Project Leader, University of Zurich, Switzerland

Data Mining in Discovery Research – Learning from the Past
Jonas Lee, PhD, Scientist, Biologics, Amgen

Integral-Molecular_NEWImmunizing Divergent Species as a MAb Discovery Strategy for Difficult Targets
Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular

PANEL DISCUSSION

Membrane Protein Tools and Technologies – What is Working and What Isn’t?
Moderator: Kevin Heyries, PhD, Co-Founder, AbCellera, Canada

Please click here to continue to the agenda for Antibody Forum – Part 2

Part 2 picks up at the transition from Discovery into Development, examining the screening approaches used for candidate selection, engineering problem solving and approaches for challenging molecules and new modalities.


 

For more details on the conference, please contact:
Kent Simmons

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 207-869-9199
Email: ksimmons@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com